At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study
In Brief
A Phase 3 clinical trial evaluating Hydroxychloroquine Sulfate and Ascorbic Acid for COVID-19 and 3 related conditions. Completed, enrolled 943 participants across 8 sites.
Detailed Summary
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. Eligible participants will be enrolled and randomized to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).
Study Details
Timeline
Interventions
Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.